Because osteonectin expression occurs in both tumor epithelial cells and bone cells, the osteonectin promoter could be used to drive a therapeutic gene co-targeting the bone metastatic prostate cancer and its supporting microenvironment, regardless of the basal level of AR and PSA expression. Here, SPARC is linked to neoplasm.